Belzutifan (MK-6482) is a potent and selective oral HIF-2alpha inhibitor with an IC50 of 9 nM, developed for clear cell renal cell carcinoma (ccRCC) research. It demonstrates efficacy in both in vitro assays and in vivo xenograft models, supporting its investigation in oncology and hypoxia-related pathways.